

Table S6. Post-vaccination immunogenicity for participants receiving 2 doses of IIV4

Measure	Strain	Half dose of IIV4		Full dose of IIV4		Comparison (95% CI)
		N	Value (95% CI)	N	Value (95% CI)	
HAI GMT	A(H1N1)	270	149 (120–185)	272	249 (203–306)	1.67 (1.24–2.26) ^a
	A(H3N2)	273	209 (170–258)	274	321 (269–383)	1.53 (1.17–2.01) ^a
	B/Victoria	270	180 (147–221)	272	233 (190–286)	1.29 (0.971–1.72) ^a
	B/Yamagata	273	169 (140–204)	274	239 (198–288)	1.41 (1.08–1.84) ^a
Seroconversion rate (%)	A(H1N1)	242	76.9 (71.0–82.0)	238	86.1 (81.1–90.3)	9.3 (2.32–16.1) ^b
	A(H3N2)	245	84.9 (79.8–89.1)	241	92.5 (88.5–95.5)	7.6 (2.00–13.3) ^b
	B/Victoria	242	85.1 (80.0–89.4)	238	84.5 (79.2–88.8)	–0.7 (–7.15–5.79) ^b
	B/Yamagata	245	84.1 (78.9–88.4)	241	88.4 (83.6–92.1)	4.3 (–1.87–10.5) ^b
Post- to pre- vaccination GMT ratio	A(H1N1)	242	8.05 (6.74–9.61)	238	16.4 (13.5–19.9)	-
	A(H3N2)	245	12.2 (10.2–14.6)	241	21.1 (17.8–25.1)	-

Measure	Strain	Half dose of IIV4		Full dose of IIV4		Comparison (95% CI)
		N	Value (95% CI)	N	Value (95% CI)	
	B/Victoria	242	12.9 (10.8–15.4)	238	17.0 (14.0–20.7)	-
	B/Yamagata	245	12.2 (10.3–14.5)	241	18.8 (15.5–22.8)	-

Immunogenicity was assessed according to the vaccine received in all participants in the immunogenicity subset who received at least one dose of the study vaccine, had a valid post-vaccination serology result for at least one strain, and completed the study according to protocol. Abbreviations: CI, confidence interval; GMT, geometric mean titer; HAI, hemagglutination inhibition; IIV4, quadrivalent split-virion inactivated influenza vaccine; -, not calculated/determined.

^a Ratio of HAI GMTs (full dose/half dose).

^b Difference in seroconversion rate: seroconversion rate for the full dose of IIV4 minus the seroconversion rate for the half dose of IIV4.